Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 501–600 of 1,001
Structural and functional specificity of H3K36 methylation
Lam, U. T. F., Tan, B. K. Y., Poh, J. J. X., & Chen, E. S. (2022) · Epigenetics & Chromatin · doi:10.1186/s13072-022-00446-7 · Cited by 91
Biomarker-driven diagnosis of diffuse gliomas
Appin, C., & Brat, D. J. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.002 · Cited by 95
FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas
Pïcca, A., Berzero, G., Bielle, F., Touat, M., Savatovsky, J., Polivka, M., Trisolini, E., Meunier, S., Schmitt, Y., Idbaïh, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005658 · Cited by 84
“N546 and K656mutations were previously reported in several other cancer types,(36,38) comprising a wide range of CNS tumors: rosette-forming glioneuronal tumors,(39) dysembryoplastic neuroepithelial tumors,(40) pilocytic astrocytomas,(41,42) diffuse leptomeningeal tumor with glial and neuronal markers,(43) and pediatr…”
BackgroundMolecular Pathology of Gliomas
Galbraith, K., & Snuderl, M. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.003 · Cited by 90
Huillard, E., Hashizume, R., Phillips, J. J., Griveau, A., Ihrie, R. A., Aoki, Y., Nicolaides, T. P., Perry, A., Waldman, T. A., McMahon, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117255109 · Cited by 87
“Recent studies have reported recurrent mutations of histone H3 and chromatin remodeling genes in pediatric GBM (6, 7).”
BackgroundResultInfluentialChang, F. T. M., McGhie, J. D., Chan, F. L., Tang, M. C., Anderson, M. A., Mann, J. R., Andy Choo, K. H., & Wong, L. H. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt114 · Cited by 76
Histone variants: nuclear function and disease
Zink, L.-M., & Hake, S. B. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.12.002 · Cited by 92
Cutter, A. R., Taneja, N., Dhakshnamoorthy, J., Wheeler, D. L., Holla, S., & Grewal, S. I. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100699118 · Cited by 86
Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Reddel, R. R. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140630101047 · Cited by 97
“Among many functions attributed to ATRX/DAXX, this complex is thought to be involved in chromatin remodeling, including telomeric deposition of the variant histone H3.”
BackgroundInfluentialEmerging Roles of ATRX in Cancer
Watson, L. A., Goldberg, H. E., & Bérubé, N. G. (2015) · Epigenomics · doi:10.2217/epi.15.82 · Cited by 89
Porter, R. S., Jaamour, F., & Iwase, S. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.10.006 · Cited by 87
Centromeric and ectopic assembly of CENP-A chromatin in health and cancer: old marks and new tracks
Sharma, A. B., Dimitrov, S. I., Hamiche, A., & Dyck, E. V. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1298 · Cited by 97
“protein expression and an abnormal mechanism of telomere maintenance called Alternative Lengthening of Telomeres (ALT) (208,213,214), which is linked to chromosomal instability (215).”
BackgroundDiffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets
Aziz‐Bose, R., & Monje, M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000577 · Cited by 85
Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities
Tétreault, M., Bareke, E., Nadaf, J., Alirezaie, N., & Majewski, J. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1039516 · Cited by 92
“The application of WES in this context has led to discovery of novel and unexpected oncogenic pathways, such as chromatin remodeling in pediatric glioblastoma [66], pre-mRNA splicing in myelodysplasia [67] or DNA methylation in acute monocytic leukemia [68].”
BackgroundSelf-citationATRX: The case of a peculiar chromatin remodeler
Ratnakumar, K., & Bernstein, E. (2012) · Epigenetics · doi:10.4161/epi.23271 · Cited by 83
DriverDB: an exome sequencing database for cancer driver gene identification
Cheng, W.-C., Chung, I.-F., Chen, C.-Y., Sun, H.-J., Fen, J.-J., Tang, W.-C., Chang, T.-Y., Wong, T.-T., & Wang, H.-W. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1025 · Cited by 82
“Moreover, ATRX has been reported as the driver gene in pediatric glioblastomas (51) and neuroblastomas (52,53).”
BackgroundArabidopsisreplacement histone variant H3.3 occupies promoters of regulated genes
Shu, H., Nakamura, M., Siretskiy, A., Borghi, L., Moraes, I., Wildhaber, T., Gruissem, W., & Hennig, L. (2014) · Genome biology · doi:10.1186/gb-2014-15-4-r62 · Cited by 81
“Recently, mutations in an H3 replacement pathway were connected to pathogenesis of glioblastoma multiforme, a lethal brain tumor [14].”
BackgroundDNA Replication Origins and Fork Progression at Mammalian Telomeres
Higa, M., Fujita, M., & Yoshida, K. (2017) · Genes · doi:10.3390/genes8040112 · Cited by 85
Essential role for centromeric factors following p53 loss and oncogenic transformation
Filipescu, D., Naughtin, M., Podsypanina, K., Lejour, V., Wilson, L., Gurard‐Levin, Z. A., Orsi, G. A., Simeonova, I., Toufektchan, E., Attardi, L. D., et al. (2017) · Genes & Development · doi:10.1101/gad.290924.116 · Cited by 84
Physical Nature of Chromatin in the Nucleus
Maeshima, K., Iida, S., & Tamura, S. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040675 · Cited by 83
“3 have been reported in pediatric gliomas (Schwartzentruber et al. 2012; Wu et al. 2012).”
BackgroundThomas, M. L., & Marcato, P. (2018) · Cancers · doi:10.3390/cancers10040101 · Cited by 82
“, which is a common driving event in pediatric brain tumors [33,34].”
BackgroundGojo, J., Pavelka, Z., Zapletalová, D., Schmook, M. T., Mayr, L., Madlener, S., Kýr, M., Vejmělková, K., Smrčka, M., Czech, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01436 · Cited by 83
Brien, G. L., Bressan, R. B., Monger, C., Gannon, D., Lagan, E., Doherty, A. M., Healy, E., Neikes, H. K., Fitzpatrick, D. J., Deevy, O., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00897-w · Cited by 85
Corpet, A., Olbrich, T., Gwerder, M., Fink, D., & Stucki, M. (2014) · Cell Cycle · doi:10.4161/cc.26988 · Cited by 71
Wood, L. D., Heaphy, C. M., Daniel, H. D.-J., Naini, B. V., Lassman, C., Arroyo, M. R., Kamel, I. R., Cosgrove, D., Boitnott, J. K., Meeker, A. K., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.68 · Cited by 80
Northcott, P. A., Pfister, S. M., & Jones, D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71206-9 · Cited by 91
Self-citationKervarrec, T., Collin, C., Larousserie, F., Bouvier, C., Aubert, S., Gomez‐Brouchet, A., Marie, B., Miquelestorena‐Standley, E., Nail, L. L., Avril, P., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.212 · Cited by 80
DAXX-dependent supply of soluble (H3.3–H4) dimers to PML bodies pending deposition into chromatin
Delbarre, E., Ivanauskiene, K., Küntziger, T. M., & Collas, P. (2012) · Genome Research · doi:10.1101/gr.142703.112 · Cited by 86
“Four amino acids guide the assembly or disassembly of Arabidopsis histone H3.”
BackgroundThe right place at the right time: chaperoning core histone variants
Mattiroli, F., D’Arcy, S., & Luger, K. (2015) · EMBO Reports · doi:10.15252/embr.201540840 · Cited by 88
“3 mutations in the same tumors [88].”
Price, G. A., Bouras, A., Hambardzumyan, D., & Hadjipanayis, C. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103453 · Cited by 87
Comba, A., Faisal, S. M., Varela, M. L., Hollon, T. C., Al‐Holou, W. N., Umemura, Y., Núñez, F. J., Motsch, S., Castro, M. G., & Lowenstein, P. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703764 · Cited by 89
Agnihotri, S., Burrell, K. E., Buczkowicz, P., Remke, M., Golbourn, B. J., Chornenkyy, Y., Gajadhar, A. S., Fernandez, N. A., Clarke, I. D., Barszczyk, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0157 · Cited by 86
El-Habr, E. A., Dubois, L. G., Burel‐Vandenbos, F., Bogeas, A., Lipecka, J., Turchi, L., Lejeune, F., Coehlo, P. L. C., Yamaki, T., Wittmann, B. M., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1659-5 · Cited by 81
“A K27M mutation [48, 58] that prevents enzymatic activity of the Polycomb repressive complex 2 [6, 33].”
BackgroundInhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
Voon, H. P. J., Udugama, M., Lin, W., Hii, L. L., Law, R. H. P., Steer, D. L., Das, P. P., Mann, J. R., & Wong, L. H. (2018) · Nature Communications · doi:10.1038/s41467-018-05607-5 · Cited by 81
Pfaff, E., Damaty, A. E., Balasubramanian, G. P., Blattner-Johnson, M., Worst, B. C., Stark, S., Witt, H., Pajtler, K. W., van Tilburg, C. M., Witt, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.019 · Cited by 83
Self-citationMitogenic and progenitor gene programmes in single pilocytic astrocytoma cells
Reitman, Z. J., Paolella, B. R., Bergthold, G., Pelton, K., Becker, S., Jones, R. E., Sinai, C. E., Malkin, H., Huang, Y., Grimmett, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11493-2 · Cited by 109
Vitanza, N. A., Biery, M. C., Myers, C. H., Ferguson, E., Zheng, Y., Girard, E. J., Przystal, J. M., Park, G., Noll, A., Pakiam, F. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa249 · Cited by 79
Funato, K., Smith, R. C., Saito, Y., & Tabar, V. S. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.02.003 · Cited by 80
Current paradigms in epigenetic anticancer therapeutics and future challenges
Singh, M. P., Kumar, V., Sehrawat, N., Yadav, M. K., Chaudhary, M., Upadhyay, S. K., Kumar, S., Sharma, V., Kumar, S., Dilbaghi, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.013 · Cited by 86
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
Koschmann, C. J., Zamler, D. B., Mackay, A. G., Robinson, D. R., Wu, Y.-M., Doherty, R. E., Marini, B. L., Tran, D., Garton, H. J. L., Muraszko, K. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11602 · Cited by 83
“Recurrent mutations in the histone gene H3F3A are seen almost exclusively in pediatric HGG, and mutations in TP53 and the histone chaperone protein ATRX are seen more frequently in pediatric HGG [5, 6].”
BackgroundMalignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
Korfhage, J. L., & Lombard, D. B. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0147 · Cited by 82
“Some of these mutations occur in conjunction with NF1 mutations (115).”
BackgroundHuang, T., García, R. M., Qi, J., Lulla, R. R., Horbinski, C., Behdad, A., Wadhwani, N. R., Shilatifard, A., James, C. D., & Saratsis, A. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26430 · Cited by 79
Halvorson, K. G., Barton, K. L., Schroeder, K., Misuraca, K. L., Hoeman, C. M., Chung, A., Crabtree, D., Cordero, F. J., Singh, R. B., Spasojević, I., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118926 · Cited by 84
Targeting epigenetic regulations in cancer
Ning, B., Li, W., Zhao, W., & Wang, R. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv116 · Cited by 84
Molecular Testing of Brain Tumor
Park, S., Won, J., Kim, S., Lee, Y., Park, C., Kim, S., & Choi, S.-H. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.03.08 · Cited by 87
“3 mutations are in pediatric GBMs (13/13), and especially associated with mutations in ATRX and DAXX.(22) Loss of ATRX is associated with the ALT phenotype; thus, ALT often coexists with mutations in ATRX/H3F3A/TP53.”
BackgroundInfluentialEnhancers: bridging the gap between gene control and human disease
Karnuta, J. M., & Scacheri, P. C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy167 · Cited by 86
“3 genes have been implicated in pediatric brain cancers (44), although the exact mechanism by which the oncohistone promotes tumorigenesis remains unresolved.”
BackgroundRoux, A., Roca, P., Edjlali, M., Sato, K., Zanello, M., Dezamis, E., Gori, P., Lion, S., Fleury, A., Dhermain, F. G., et al. (2019) · Radiology · doi:10.1148/radiol.2019190491 · Cited by 77
Clinical impact of molecular biomarkers in gliomas
Siegal, T. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.004 · Cited by 89
Cai, J., Yang, P., Zhang, C., Zhang, W., Liu, Y., Bao, Z., Liu, X., Du, W., Wang, H., Jiang, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1838 · Cited by 80
“In several previous studies, ATRX mutation was reported to be strongly correlated with its loss of expression, and may predict better prognosis in astrocytic tumors with IDH mutations [13, 15, 21, 22].”
BackgroundSelf-citationLehnertz, B., Zhang, Y. W., Boivin, I., Mayotte, N., Tomellini, E., Chagraoui, J., Lavallée, V., Hébert, J., & Sauvageau, G. (2017) · Blood · doi:10.1182/blood-2017-03-774653 · Cited by 81
Ren, Z., Ahn, J. H., Liu, H., Tsai, Y., Bhanu, N. V., Koss, B. S., Allison, D. F., Ma, A., Storey, A. J., Wang, P., et al. (2019) · Blood · doi:10.1182/blood.2019000578 · Cited by 80
Khazaei, S., Jay, N. D., Deshmukh, S., Hendrikse, L. D., Jawhar, W., Chen, C. C. L., Mikael, L. G., Faury, D., Marchione, D. M., Lanoix, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0461 · Cited by 79
“3G34R/V) that arise in brain tumours and co-occur with partner TP53 and ATRX mutations (3,4), H3.”
BackgroundSelf-citationCharacteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults
Picart, T., Barritault, M., Poncet, D., Berner, L.-P., Izquierdo, C., Tabouret, É., Figarella‐Branger, D., Idbaïh, A., Bielle, F., Bourg, V., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab061 · Cited by 86
“The inclusion criteria were the following: (1) age ≥ 18 years, (2) available MRI for radiological review, (3) and available TERT promoter mutation status for IDH-wildtype glioblastomas.”
BackgroundRethinking pheochromocytomas and paragangliomas from a genomic perspective
Castro‐Vega, L. J., Lussey‐Lepoutre, C., Gimenez‐Roqueplo, A., & Favier, J. (2015) · Oncogene · doi:10.1038/onc.2015.172 · Cited by 84
Lober, R. M., Cho, Y., Tang, Y., Barnes, P. D., Edwards, M. S. B., Vogel, H. S., Fisher, P. G., Monje, M., & Yeom, K. W. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1375-8 · Cited by 79
Pediatric gliomas as neurodevelopmental disorders
Baker, S. J., Ellison, D. W., & Gutmann, D. H. (2015) · Glia · doi:10.1002/glia.22945 · Cited by 82
Taylor, I. C., Hütt-Cabezas, M., Brandt, W. D., Kambhampati, M., Nazarian, J., Chang, H. T., Warren, K. E., Eberhart, C. G., & Raabe, E. H. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000216 · Cited by 81
“These expression profile cohorts do not overlap with groups defined byH3F3Amutations (15,16,19), suggesting an added complexity to DIPG biology.”
BackgroundHDAC Inhibition to Prime Immune Checkpoint Inhibitors
Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., & Le Tourneau, C. (2021) · Cancers · doi:10.3390/cancers14010066 · Cited by 75
“Histone methylation dysregulation can also occur through various mechanism like mutations in gene encoding for enhancer of zeste homologue 2 (EZH2), the first methyltransferase responsible for the H3K27me3 histone modification, for example [18], or in some cases through oncogenic driver mutations directly in histone g…”
BackgroundLiang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-18-3374 · Cited by 75
The adjustable nucleosome: an epigenetic signaling module
Turner, B. M. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.04.003 · Cited by 82
Malzkorn, B., & Reifenberger, G. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000327 · Cited by 79
Self-citationPediatric diffuse intrinsic pontine glioma: where do we stand?
Rashed, W. M., Maher, E., Adel, M., Saber, O., & Zaghloul, M. S. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09824-2 · Cited by 80
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
Balakrishnan, I., Danis, E., Pierce, A., Madhavan, K., Wang, D., Dahl, N., Sanford, B., Birks, D. K., Davidson, N., Metselaar, D. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108286 · Cited by 69
“This is an open access article under the CC BY-N DIPG and is associated with aggressive tumor growth and poor survival (Schwartzentruber et al., 2012; Sturm et al., 2014; Warren et al., 2012; Wu et al., 2012).”
BackgroundSelf-citationHistone H3.3 Is Required to Maintain Replication Fork Progression after UV Damage
Frey, A., Listovsky, T., Guilbaud, G., Sarkies, P., & Sale, J. E. (2014) · Current Biology · doi:10.1016/j.cub.2014.07.077 · Cited by 79
“Because S31 lies close to these residues, we wondered whether the cancer-associated mutations K27M, G34R, and G34V [19, 20] might also confer sensitivity to DNA damage.”
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 85
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript (H3K27M) (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012a).”
BackgroundKoelsche, C., Schrimpf, D., Tharun, L., Roth, E. K., Sturm, D., Jones, D., Renker, E.-K., Sill, M., Baude, A., Sahm, F., et al. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0075-5 · Cited by 80
“3 mutant brain tumors, which typically present at younger age than their wild-type adult counterparts [15, 27].”
BackgroundSelf-citationRecent advances in intradural spinal tumors
Abd‐El‐Barr, M. M., Huang, K. T., Moses, Z. B., Iorgulescu, J. B., & Chi, J. H. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox230 · Cited by 79
Histone variant macroH2A: from chromatin deposition to molecular function
Sun, Z., & Bernstein, E. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180062 · Cited by 79
Williams, J. R., Young, C. C., Vitanza, N. A., McGrath, M., Feroze, A. H., Browd, S. R., & Hauptman, J. S. (2020) · Neurosurgical FOCUS · doi:10.3171/2019.9.focus19745 · Cited by 81
“32,62,71 Immuno-chemistry is the most cost-efficient test for H3K27M mu - tations but cannot distinguish among them, and mutation variants have proven clinically important.”
Shankar, G. M., Lelic, N., Gill, C. M., Thorner, A. R., Hummelen, P. V., Wisoff, J. H., Loeffler, J. S., Brastianos, P. K., Shin, J. H., Borges, L. F., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1492-2 · Cited by 74
“The age distribution of our findings are consistent with prior observations that H3F3A K27M primarily occurs in pediatric and young adult gliomas [11, 15, 19].”
BackgroundResultWood, M. D., Halfpenny, A. M., & Moore, S. R. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0802-8 · Cited by 82
Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements
Kim, G. B., Pacheco, D. R. F., Saxon, D. S., Yang, A., Sabet, S., Dutra‐Clarke, M., Levy, R., Watkins, A., Park, H., Akhtar, A. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.013 · Cited by 79
“For example, H3F3A mutations are often coincident with recurrent dominantactive Pdgfra (D842V) and dominant-negative Trp53 (R270H) (Schwartzentruber et al., 2012; Mackay et al., 2017).”
de Billy, E., Pellegrino, M., Orlando, D., Pericoli, G., Ferretti, R., Businaro, P., Ajmone‐Cat, M. A., Rossi, S., Petrilli, L. L., Maestro, N., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab300 · Cited by 84
Plasmid DNA for Therapeutic Applications in Cancer
Martínez-Puente, D. H., Perez‐Trujillo, J. J., Zavala-Flores, L. M., García‐García, A., Villanueva-Olivo, A., Rodríguez‐Rocha, H., Valdés, J., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., & Loera‐Arias, M. D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091861 · Cited by 79
Monje, M., Cooney, T. M., Glod, J. W., Huang, J., Peer, C. J., Faury, D., Baxter, P. A., Kramer, K., Lenzen, A. C., Robison, N. J., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad141 · Cited by 82
Self-citationGessi, M., Gielen, G. H., Hammes, J., Dörner, E., Mühlen, A. Z., Waha, A., & Pietsch, T. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1040-z · Cited by 74
Pediatric low-grade gliomas: How modern biology reshapes the clinical field
Bergthold, G., Bandopadhayay, P., Bi, W. L., Ramkissoon, L. A., Stiles, C. D., Segal, R. A., Beroukhim, R., Ligon, K. L., Grill, J., & Kieran, M. W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.004 · Cited by 83
Potential Epigenetic-Based Therapeutic Targets for Glioma
Zang, L., Kondengaden, S. M., Che, F., Wang, L., & Heng, X. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00408 · Cited by 77
“In pediatric GBM, H3F3A involves two critical singlepoint mutations in the histone tail at lysine (K) 27 (K27M) and glycine (G) 34 (G34R/V) that are both involved with key regulatory post-transcriptional modifications (Schwartzentruber et al., 2012).”
BackgroundOncogenic Mechanisms of Histone H3 Mutations
Weinberg, D. N., Allis, C. D., & Lü, C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026443 · Cited by 78
“Similar to other cancer types, ATRX-mutant pHGGs show alternative lengthening of telomeres (Schwartzentruber et al. 2012).”
BackgroundResultInfluentialAutomated in situ chromatin profiling efficiently resolves cell types and gene regulatory programs
Janssens, D. H., Wu, S. J., Sarthy, J. F., Meers, M. P., Myers, C. H., Olson, J. M., Ahmad, K., & Henikoff, S. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0243-8 · Cited by 73
Zheng, Y., Fornelli, L., Compton, P. D., Sharma, S., Canterbury, J., Mullen, C., Zabrouskov, V., Fellers, R. T., Thomas, P. M., Licht, J. D., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.053819 · Cited by 73
Kumar, R., Liu, A. P. Y., Orr, B. A., Northcott, P. A., & Robinson, G. W. (2018) · Cancer · doi:10.1002/cncr.31583 · Cited by 74
“3 now characterize pediatric glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG).(80,81) Sturm et al have since identified 6 epigenetic subgroups (K27, G34, IDH, RTK I, RTK II, and mesenchymal).”
BackgroundHistone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones
Sarthy, J. F., Meers, M. P., Janssens, D. H., Henikoff, J. G., Feldman, H. M., Paddison, P. J., Lockwood, C. M., Vitanza, N. A., Olson, J. M., Ahmad, K., et al. (2020) · eLife · doi:10.7554/elife.61090 · Cited by 76
WHSC1 links transcription elongation to HIRA‐mediated histone H3.3 deposition
Sarai, N., Nimura, K., Tamura, T., Kanno, T., Patel, M. C., Heightman, T. D., Ura, K., & Ozato, K. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.176 · Cited by 74
“3 deposition pathways were reported in malignant brain tumours (Schwartzentruber et al , 2012; Wu et al , 2012).”
Epigenetic dysregulation in glioma
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., & Shinjo, K. (2014) · Cancer Science · doi:10.1111/cas.12379 · Cited by 81
Chang, F. T. M., Chan, F. L., R. McGhie, J. D., Udugama, M., Mayne, L., Collas, P., Mann, J. R., & Wong, L. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv104 · Cited by 66
“Human ALT cancers show high mutation rates in ATRX and DAXX.”
BackgroundInfluentialHuman pontine glioma cells can induce murine tumors
Caretti, V., Sewing, A. C. P., Lagerweij, T., Schellen, P., Bugiani, M., Jansen, M. H. A., van Vuurden, D. G., Navis, A. C., Horsman, I., Vandertop, W. P., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1272-4 · Cited by 73
“Although DIPg shares recurrent aberrations in histone 3 genes with supratentorial pediatric gliomas, they are molecularly distinct tumors [42, 43, 49].”
BackgroundInfluentialUtility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas
Ikemura, M., Shibahara, J., Mukasa, A., Takayanagi, S., Aihara, K., Saito, N., Aburatani, H., & Fukayama, M. (2016) · Histopathology · doi:10.1111/his.12927 · Cited by 74
“In paediatric gliomas, ATRX mutation frequently accompanies H3F3A mutation in the absence of IDH mutation.(23) In adults, diffuse (midline) gliomas of the thalamus, brain stem and spinal cord frequently show similar genetic traits, namely H3F3A mutation without IDH mutation, and these tumours tend to affect younger pa…”
BackgroundCompendium of aberrant DNA methylation and histone modifications in cancer
Hattori, N., & Ushijima, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.140 · Cited by 77
Epigenetic pathways and glioblastoma treatment
Clarke, J., Penas, C., Pastori, C., Komotar, R. J., Bregy, A., Shah, A. H., Wahlestedt, C., & Ayad, N. G. (2013) · Epigenetics · doi:10.4161/epi.25440 · Cited by 76
“For example, Schwatzentruber et al.15 demonstrated that somatic mutations in the H3.”
The Multiple Facets of PRC2 Alterations in Cancers
Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 74
Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma
Lopez, G. Y., Bush, N. A. O., Berger, M. S., Perry, A., & Solomon, D. A. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0440-x · Cited by 71
“As only a couple prior examples of such cortically-based diffuse gliomas with H3 K27M mutation have been reported [7, 9], the prognostic significance of this combination of histologic and genetic features is uncertain at present, as is optimal therapy.”
BackgroundCharacterizing temporal genomic heterogeneity in pediatric high-grade gliomas
Salloum, R., McConechy, M. K., Mikael, L. G., Fuller, C. E., Drissi, R., DeWire, M. D., Nikbakht, H., Jay, N. D., Yang, X., Boué, D. R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0479-8 · Cited by 74
“H3/IDH1 wildtype pHGGs have previously been shown to be a diverse group of tumors with mutations in many cancer pathways [35, 37, 51], but have not been directly linked to any particular epigenetic driver as is the case with H3 and IDH1 mutant tumors.”
Self-citationSpinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation
Alvi, M. A., Ida, C. M., Paolini, M. A., Kerezoudis, P., Meyer, J., Fritcher, E. G. B., Goncalves, S., Meyer, F. B., Bydon, M., & Raghunathan, A. (2019) · Modern Pathology · doi:10.1038/s41379-019-0271-3 · Cited by 74
Pediatric high‐grade glioma: moving toward subtype‐specific multimodal therapy
Chatwin, H. V., Cruz, J. C., & Green, A. L. (2021) · FEBS Journal · doi:10.1111/febs.15739 · Cited by 76
“14 Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, T€ onjes M et al. (2012) Driver mutations in histone H3.”
BackgroundSingle substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration
Khazaei, S., Chen, C. C. L., Andrade, A. F., Kabir, N., Azarafshar, P., Morcos, S. M., França, J. A., Lopes, M. D. C., Lund, P. J., Danieau, G., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.023 · Cited by 74
Self-citationA global assessment of cancer genomic alterations in epigenetic mechanisms
Shah, M. A., Denton, E., Arrowsmith, C. H., Lupien, M., & Schapira, M. (2014) · Epigenetics & Chromatin · doi:10.1186/1756-8935-7-29 · Cited by 75
“Other examples include recurrent mutations of the chromatin remodeling protein ATRX in lower grade glioblastoma (40% of patient) [20], or DNMT3A and TET2 in acute myeloid leukemia (25% and 8.”
BackgroundSex differences of leukocytes DNA methylation adjusted for estimated cellular proportions
Inoshita, M., Numata, S., Tajima, A., Kinoshita, M., Umehara, H., Yamamori, H., Hashimoto, R., Imoto, I., & Ohmori, T. (2015) · Biology of Sex Differences · doi:10.1186/s13293-015-0029-7 · Cited by 82
“3, has been implicated in glioblastoma [37, 38].”
Pollack, I. F., Jakacki, R. I., Butterfield, L. H., Hamilton, R. L., Panigrahy, A., Normolle, D. P., Connelly, A. K., Dibridge, S., Mason, G. E., Whiteside, T. L., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2245-3 · Cited by 71
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 79
“Up to 80% of DIPGs harbor a mutation in H3K27M (Schwartzentruber et al., 2012; Wu et al., 2012; Buczkowicz et al., 2014; Fontebasso et al., 2014; Taylor et al., 2014), resulting in global reductions in H3K27me3 levels (Lewis et al.”
Background
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.